Wegovy (injectable)

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly subcutaneous injection from Novo Nordisk. The FDA approved Wegovy for chronic weight management in June 2021, making it the first truly effective weight-loss drug launched in a generation.

Semaglutide is a GLP-1 receptor agonist — a synthetic analog of the gut hormone glucagon-like peptide-1. It slows gastric emptying, blunts hunger signaling through hypothalamic GLP-1 receptors, and improves insulin secretion in response to meals. Unlike tirzepatide (Zepbound), semaglutide hits only the GLP-1 receptor — not GIP — which is why head-to-head efficacy favors tirzepatide.

The same molecule is sold under two other brand names: Ozempic (1.0 mg / 2.0 mg for type 2 diabetes) and Rybelsus (7 / 14 mg oral tablet for diabetes). Wegovy uses the highest dose (2.4 mg weekly) because the dose-response for weight loss is steeper than for glycemic control. Starting in January 2026, a fourth brand — the Wegovy Pill — brought an oral 25 mg version to the obesity market.

The pivotal efficacy trial was STEP-1, a 68-week placebo-controlled study of 1,961 adults with BMI ≥30 or ≥27 with a weight-related condition. Published in the New England Journal of Medicine in 2021, STEP-1 showed a mean body weight reduction of 14.9% on semaglutide 2.4 mg versus 2.4% on placebo. About 86% of treated patients lost at least 5% of body weight; 50% lost 15% or more.

STEP-2 tested semaglutide in adults with type 2 diabetes (about 10% mean weight loss — less than non-diabetic patients, a pattern seen with every GLP-1). STEP-3 paired semaglutide with intensive behavioral therapy (16% weight loss). STEP-4 studied what happens after stopping: patients who continued drug maintained losses, while those switched to placebo regained weight on a similar trajectory to Zepbound's SURMOUNT-4.

The head-to-head SURMOUNT-5 trial (2025) compared semaglutide 2.4 mg to tirzepatide 10–15 mg and found tirzepatide produced about 47% greater weight loss. But Wegovy has its own unique claim to fame: SELECT (2023, NEJM) showed a 20% relative reduction in major adverse cardiovascular events (heart attack, stroke, CV death) in adults with obesity and established heart disease. No other obesity drug has matched this evidence.

Wegovy is a once-weekly subcutaneous injection via pre-filled pen. The titration schedule is 0.25 mg for 4 weeks → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (maintenance), with 4 weeks at each dose. The full escalation takes 16–20 weeks.

Each dose comes in its own pen color, which is both a dose-confirmation feature and — historically — a source of the supply shortages Novo faced through 2022–2024. The pen is used once per week on the same day, injected into the abdomen, thigh, or upper arm.

If GI side effects are intolerable at a given dose, patients typically stay on the prior dose for an additional 4 weeks before attempting escalation again. Some patients remain on 1.7 mg as a maintenance dose rather than pushing to 2.4 mg.

Wegovy's side effects profile is very similar to tirzepatide's. In STEP-1 the most common were nausea (44%), diarrhea (32%), vomiting (25%), constipation (24%), abdominal pain (20%), and headache (16%). The higher nausea rate vs. tirzepatide in trials likely reflects the 68-week duration plus the population (treatment-naive).

Class-level risks mirror Zepbound: acute pancreatitis, gallbladder disease, acute kidney injury from dehydration, hypoglycemia with insulin/sulfonylureas, and diabetic retinopathy complications in at-risk patients. A boxed warning for thyroid C-cell tumors applies; contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2.

Semaglutide has been on the market since 2017 across Ozempic/Rybelsus/Wegovy — the longest real-world surveillance of any obesity-specific GLP-1. Post-marketing signals have appeared for ileus and bowel obstruction (rare), gastroparesis-like symptoms that persist after stopping, and aspiration risk during general anesthesia if the drug isn't held 1 week pre-op. The American Society of Anesthesiologists recommends holding weekly GLP-1s for one week before elective surgery.

Wegovy's list price is approximately $1,349/month through retail pharmacy. Few patients pay list.

Commercial insurance: most commercial plans cover Wegovy with prior authorization. With coverage, the Wegovy Savings Card typically brings out-of-pocket to $0–$25/month.

Cash through NovoCare Pharmacy: Novo's direct-to-patient program offers Wegovy at $499/month (all doses, delivered) for cash-pay patients — a direct response to LillyDirect's Zepbound Self Pay.

Medicare: Part D does not cover Wegovy for weight management. However, a 2024 CMS clarification allows Part D coverage of Wegovy for the cardiovascular risk reduction indication (post-SELECT) in patients with established heart disease — a narrow but meaningful carve-out.

Medicaid: varies by state; about half of state Medicaid programs include Wegovy on formulary with PA.

Compounded semaglutide: semaglutide was on the FDA drug shortage list from 2022 through mid-2025. Novo successfully petitioned removal in 2025, ending most 503A/503B compounding of identical semaglutide. Some telehealth programs continue to sell semaglutide sodium (a research-grade salt form) of uncertain equivalence; quality varies widely.

For current cash, insurance, and program-level pricing, see our GLP-1 program comparison.

FDA label eligibility is identical to Zepbound: BMI ≥ 30, or BMI ≥ 27 with a weight-related comorbidity. Wegovy is also approved to reduce risk of major cardiovascular events in adults with established cardiovascular disease and obesity — a label no competitor shares.

Wegovy is the strongest choice when:

• You have established heart disease and want the SELECT evidence behind your drug.
• Your insurance covers Wegovy but not Zepbound (coverage varies by plan and changes annually).
• You have a stable response at a maintenance dose and don't need tirzepatide's maximum efficacy.
• You value the longer real-world safety record.

It's a weaker choice if you need maximum weight loss (prefer Zepbound), if you cannot tolerate injections (consider Wegovy Pill or oral orforglipron when approved), or if your insurance won't cover it and you can access lower-cost alternatives.

Pathways mirror Zepbound:

1. In-person prescriber + retail pharmacy: your PCP or obesity medicine specialist writes the script; insurance handles PA; you fill at retail or via NovoCare.

2. Telehealth program: Ro, Form Health, Mochi, PlushCare, and WeightWatchers Clinic all prescribe Wegovy. Monthly platform fees range from $59 to $199.

3. NovoCare Pharmacy cash program: $499/month direct from Novo's fulfillment pharmacy; requires any valid U.S. prescription.

If cost is the main question, run the Sherpa Matcher — it cross-references your insurance, goals, and preferred form to surface the lowest out-the-door price.